Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141277 | 0.85 | ADORA2A (0.58) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL4905916 | 0.85 | ADORA1 (0.77) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL15286448 | 0.83 | ADORA1 (0.67) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL6441069 | 0.82 | RXFP1 (1.00) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL4421002 | 0.82 | RXFP1 (0.61) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL4899129 | 0.82 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL4904046 | 0.81 | ADORA1 (0.58) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL7777554 | 0.80 | ADORA2A (0.58) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL7774476 | 0.80 | ADORA2A (0.58) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL7777497 | 0.80 | ADORA2A (0.58) | ADORA1ADORA2AADORA2BMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | ADORA1 529/4885ADORA2A 837/4885ADORA2B 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.